Genetic Test for Triple Negative Breast Cancer Tells who Will and Won’t Respond to Immunotherapy
May 28, 2024 | Terry Sharrer
“A genetic test developed at the University of California San Francisco (UCSF) can identify triple negative breast cancer patients who will and won’t respond to commonly used immunotherapies. . . . . “This new work now presents an update of the ImPrint classifier specifically for triple negative breast cancers, ImPrintTN. We found that it can predict patients who are unlikely to respond to immunotherapy, so that the harms from the treatment are greater than the benefit. This means it would be acceptable for them to forgo an immunotherapy drug in order to avoid the risk of these sometimes life-long irreversible adverse effects.” MORE
Image Credit: InsidePrecisionMedicine